Immupharma PLC Total Share Capital Notification - Replacement (6454F)
November 18 2020 - 2:00AM
UK Regulatory
TIDMIMM
RNS Number : 6454F
Immupharma PLC
18 November 2020
RNS | eCorporate 18 November 2020
ImmuPharma PLC
("ImmuPharma" or the "Company")
Total Share Capital Notification - Replacement
The following replaces the 'Total Share Capital Notification'
announcement released on 30 September 2020 at 7.01am (BST) under
RNS No 5041A.
In Section 2 below the reference to "Share Options in whole or
part" should have stated 25,640,254 not 15,703,942.
The full amended text is shown below.
ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the
specialist drug discovery and development company announces that in
accordance with its obligations to the Company's Euronext listing
and following an application of Article 15 of the Belgian Law of 2
May 2007, the total number of shares with voting rights and the
total number of voting rights are set out below:
Situation as at 16 June 2020
1. Information to be provided for on the basis
of Article 15, --1, al. 1
Total of share capital (nominal value) : GBP 24,628,580
Total number of shares with existing voting
rights (= denominator) - one vote per share : 246,285,805
2. Additional information to be provided on
the basis of Article 15, --1, al. 2
In respect to the announcement on 11 June
2020: "Investment from two specialist US healthcare
investors"
Convertible Securities (in whole or in part)
into ordinary shares currently outstanding.
The total conversion would result in an equal
number of voting rights : 10,734,166
Share options (in whole or in part)
The exercise of the options would result in
the creation of an equal number of ordinary
shares and voting rights. : 25,640,254
In respect to the announcements on 30 March
2020: "Subscription to raise GBP1.5m" and
2 September 2020 "Placing to raise GBP6.5m"
Warrants over ordinary shares (in whole or
in part)
The exercise of the warrants would result
in the creation of an equal number of ordinary
shares and voting rights : 3,343,045
Other outstanding rights to subscribe ordinary
shares as detailed in the Annual Report 2019
(Report and consolidated financial Statements
for the year ended 31 December 2019)
Share options (in whole or in part)
The exercise of the options would result in
the creation of an equal number of ordinary
shares and voting rights : 16,368,850
This situation (the denominator) serves as a basis for the
notification of major holdings by shareholders.
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 20 3 36 8 3550
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Gunther De Backer +32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, metabolic diseases,
anti-infectives and cancer. The lead program, Lupuzor(TM), is a
first-in class autophagy immunomodulator which is in Phase III for
the treatment of lupus and preclinical analysis suggest therapeutic
activity for many other autoimmune diseases that share the same
autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals
signed on 28 November 2019, an exclusive licence and development
agreement and trademark agreement for Lupuzor(TM) to fund a new
international Phase III trial for Lupuzor(TM) and commercialise in
the US.
For additional information about ImmuPharma please visit
www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code:
213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRBRBPTMTJBBMM
(END) Dow Jones Newswires
November 18, 2020 02:00 ET (07:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024